A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292in Pediatric Patients with Advanced RET-Altered Solid orPrimary Central Nervous System Tumors

Project: Research project

Project Details

Description

A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
StatusActive
Effective start/end date5/15/205/31/24

Funding

  • LOXO ONCOLOGY

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.